CytomX Therapeutics, Inc. (CTMX) Net margin 2016–2025
CytomX Therapeutics, Inc. (CTMX) net profit margin by fiscal year — reported net income divided by reported revenue.
-22.8%FY2025 · since FY2016: -458.5% → -22.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -22.8% | -45.9 pp |
| FY2024 | 23.1% | +23.6 pp |
| FY2023 | -0.6% | +186.3 pp |
| FY2022 | -186.8% | +123.7 pp |
| FY2021 | -310.5% | -215.8 pp |
| FY2020 | -94.7% | +399.0 pp |
| FY2019 | -493.7% | -351.5 pp |
| FY2018 | -142.2% | -82.0 pp |
| FY2017 | -60.2% | +398.4 pp |
| FY2016 | -458.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice